Capital Group Investment Management PTE. LTD. Acquires Shares of 6,478 Icon Plc $ICLR

Capital Group Investment Management PTE. LTD. acquired a new stake in Icon Plc (NASDAQ:ICLR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 6,478 shares of the medical research company’s stock, valued at approximately $1,180,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC increased its holdings in shares of Icon by 1.1% in the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after purchasing an additional 56 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of Icon by 11.5% in the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 56 shares during the period. New Wave Wealth Advisors LLC increased its holdings in shares of Icon by 5.1% in the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 72 shares during the period. Signaturefd LLC increased its holdings in shares of Icon by 12.6% in the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after purchasing an additional 72 shares during the period. Finally, 1900 Wealth Management LLC increased its holdings in shares of Icon by 4.4% in the fourth quarter. 1900 Wealth Management LLC now owns 2,430 shares of the medical research company’s stock valued at $443,000 after purchasing an additional 103 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Icon Stock Performance

NASDAQ ICLR opened at $149.45 on Friday. The business’s 50-day moving average price is $117.51 and its 200 day moving average price is $140.85. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The company has a market capitalization of $12.07 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 10.13 and a beta of 1.26. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last released its earnings results on Wednesday, May 27th. The medical research company reported $2.21 earnings per share for the quarter. Icon had a return on equity of 9.50% and a net margin of 5.98%.The firm had revenue of $2.11 billion for the quarter. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, research analysts predict that Icon Plc will post 9.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ICLR has been the topic of a number of recent research reports. Jefferies Financial Group reissued a “buy” rating and issued a $165.00 target price on shares of Icon in a report on Friday, May 29th. TD Cowen upped their price objective on Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Citigroup upped their price objective on Icon from $120.00 to $140.00 and gave the stock a “neutral” rating in a report on Friday, May 29th. Robert W. Baird set a $119.00 price objective on Icon in a report on Friday, February 13th. Finally, Rothschild & Co Redburn set a $100.00 price objective on Icon and gave the stock a “neutral” rating in a report on Tuesday, February 17th. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $156.44.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.